机构：[1]School of Medicine, Shandong University, Jinan, Shandong, China,[2]Department of Breast Surgery, the Second Hospital of Shandong University, Jinan, Shandong, China[3]Breast Disease Center, Peking University First Hospital, Beijing, China[4]Department of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan, China河南省肿瘤医院[5]Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan, Shanxi, China[6]National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,[7]Breast Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China河北医科大学第四医院外一科临床科室[8]Department of Breast Surgery, the First Hospital of Jilin University, Changchun, Jilin, China[9]Department of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China[10]Breast Disease Center, Peking University People's Hospital, Beijing, China, [11]Department of General Surgery, Beijing Chaoyang Hospital, Beijing, China北京朝阳医院[12]Department of General Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, [13] Department of Breast Surgery, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China[14]Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China[15] Department of General Surgery, Linyi People’s Hospital, Linyi, Shandong, China[16]Department of Thyroid and Breast Surgery, the First Affiliated hospital of Binzhou Medical University, Binzhou, Shandong, China[17]Breast Center, Qingdao University Affiliated Hospital, Qingdao, Shandong, China[18]Department of Breast Surgery, the Second Affiliated Hospital of Qingdao Medical College, Qingdao Central Hospital, Qingdao, Shandong, China[19] Department of Breast and Thyroid Surgery, Weifang Traditional Chinese Hospital, Weifang, Shandong, China, [20]Department of Breast and Thyroid Surgery, Zibo Central Hospital, Zibo, Shandong, China, [21] Department of Breast Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong, China,[22]Breast Cancer Center, Shandong Cancer Hospital, Jinan, Shandong, China[23]Epidemiology Institute, School of Public Health, Shandong University, Jinan, Shandong, China[24]Division of Epidemiology and Biostatistics, School of Public Health, Shandong University, Jinan, Shandong, China
The level of total adiponectin, a mixture of different adiponectin forms, has been reported associated with breast cancer risk with inconsistent results. Whether the different forms play different roles in breast cancer risk prediction is unclear. To examine this, we measured total and high molecular weight (HMW) adiponectin in a case-control study (1167 sets). Higher circulating HMW adiponectin was negatively associated with breast cancer risk after adjusting for menopausal status and family history of breast cancer (P=0.024). We analyzed the relationship between adiponectin and breast cancer risk in 6 subgroups. Higher circulating HMW adiponectin was also negatively associated with breast cancer risk (P=0.020, 0.014, 0.035) in the subgroups of postmenopausal women, negative family history of breast cancer, BMI>=24.0. Total adiponectin was positively associated with breast cancer (P=0.028) in the subgroup of BMI<=24.0. Higher HMW/total adiponectin ratio was negatively associated with breast cancer (P=0.019) in the subgroup of postmenopausal women. Interestingly, in the subgroup of women with family history of breast cancer, higher circulating total and HMW adiponectin were positively associated with breast cancer risk (P=0.034, 0.0116). This study showed different forms of circulating adiponectin levels might play different roles in breast cancer risk. A higher circulating HMW adiponectin is associated with a decreased breast cancer risk, especially in postmenopausal, without family history of breast cancer or BMI>=24.0 subgroups, whereas higher circulating HMW adiponectin levels is a risk factor in women with a family history of breast cancer. Further investigation of different forms of adiponectin on breast cancer risk is needed.
基金：
This study is supported by two programs:
one is the Key Project of the Natural Science
Foundation of Shandong Province, China
(ZR2014HZ004);
another one is the Clinical Scientific Research Project
of Science and Technology Agency of Jiangsu
Province, China (BL2014055,)
ZGY is the author who received the funding above.
第一作者机构：[1]School of Medicine, Shandong University, Jinan, Shandong, China,[2]Department of Breast Surgery, the Second Hospital of Shandong University, Jinan, Shandong, China
通讯作者：
推荐引用方式(GB/T 7714)：
Ming-ming Guo,Xue-ning Duan,Shu-de Cui,et al.Circulating High-Molecular-Weight (HMW) Adiponectin Level Is Related with Breast Cancer Risk Better than Total Adiponectin: A Case-Control Study.[J].PLOS ONE.2015,10(6):doi:10.1371/journal.pone.0129246.
APA：
Ming-ming Guo,Xue-ning Duan,Shu-de Cui,Fu-guo Tian,Xu-chen Cao...&Zhi-gang Yu.(2015).Circulating High-Molecular-Weight (HMW) Adiponectin Level Is Related with Breast Cancer Risk Better than Total Adiponectin: A Case-Control Study..PLOS ONE,10,(6)
MLA：
Ming-ming Guo,et al."Circulating High-Molecular-Weight (HMW) Adiponectin Level Is Related with Breast Cancer Risk Better than Total Adiponectin: A Case-Control Study.".PLOS ONE 10..6(2015)
